Related Experiment Video
Updated: Jun 15, 2025
08:14
A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
Published on: August 28, 2018
8.1K
Chasing LDL cholesterol to the bottom - PCSK9 in perspective.
Peter Libby1, Lale Tokgözoğlu2
1Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. plibby@bwh.harvard.edu.
Nature Cardiovascular Research
|August 28, 2024
Summary
Lowering low-density lipoprotein cholesterol (LDL-C) effectively prevents atherosclerosis. New proprotein convertase subtilisin/kexin type 9 (PCSK9) therapies significantly reduce LDL-C, improving cardiovascular outcomes.
Area of Science:
- Cardiovascular Medicine
- Molecular Biology
- Pharmacology
Background:
- Low-density lipoprotein (LDL) is a causal factor in atherosclerosis, a major global health issue.
- Therapeutic lowering of LDL cholesterol (LDL-C) has significantly reduced cardiovascular disease burden.
- Autosomal-dominant hypercholesterolemia research identified proprotein convertase subtilisin/kexin type 9 (PCSK9) as a key genetic driver.
Purpose of the Study:
- To review the impact of LDL-C lowering therapies on atherosclerotic events.
- To highlight the significance of PCSK9 in developing novel LDL-C reduction strategies.
- To discuss the collaborative efforts driving advancements in cardiovascular disease prevention.
Main Methods:
- Review of existing literature on LDL-C, atherosclerosis, and therapeutic interventions.
- Analysis of the role of PCSK9 in lipid metabolism and cardiovascular risk.
- Examination of the development and impact of PCSK9-targeting agents.
Main Results:
- Therapeutic interventions effectively lower LDL-C and improve cardiovascular outcomes.
- PCSK9 inhibition represents a significant advancement, enabling unprecedented LDL-C reduction.
- Novel PCSK9 agents have demonstrated substantial efficacy in mitigating cardiovascular risk.
Conclusions:
- The development of PCSK9-targeting therapies marks a major success in cardiovascular medicine.
- Successful partnerships between basic science, industry, and clinical research are crucial for progress.
- Continued collaboration holds promise for further advancements in combating cardiovascular diseases.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
596
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
596
01:29Cholesterol: Significance and Regulation
520
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
520
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
499
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
499
01:23Dipeptidyl Peptidase 4 Inhibitors
178
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
147
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
147
01:18Lipids: Dietary Sources and Requirements
708
Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ...
708